Camrelizumab - Jiangsu Hengrui Medicine
Alternative Names: AiRuiKa; Carbarizumab; Carrizumab; HR-301210; INCSHR-1210; SHR 1210; SHR01210Latest Information Update: 06 Jun 2025
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Developer Chinese PLA General Hospital; CrystalGenomics; Fudan University; Fudan University Shanghai Cancer Center; Guangzhou Institute of Respiratory Disease; Hangzhou Cancer Hospital; Henan Cancer Hospital; Incyte Corporation; Jiangsu Hengrui Medicine Co.; Nanjing Medical University; Peking University People's Hospital; Sun Yat-Sen University; Suzhou Suncadia Biopharmaceuticals; Tianjin Medical University Cancer Institute and Hospital; West China Hospital Sichuan University
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cervical cancer; Hodgkin's disease; Liver cancer; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer
- Phase III Gastric cancer; Squamous cell cancer; Triple negative breast cancer
- Phase II Acral lentiginous melanoma; Biliary cancer; Breast cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Gastrointestinal cancer; Glioblastoma; HER2 negative breast cancer; Lung cancer; Malignant fibrous histiocytoma; Malignant melanoma; Osteosarcoma; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Thyroid cancer; Urogenital cancer; Uterine cancer
- Phase I/II Bladder cancer; Diffuse large B cell lymphoma
Most Recent Events
- 29 May 2025 Launched for Cervical cancer (Recurrent, Second-line therapy or greater, Metastatic disease, Combination therapy) in China (IV)
- 29 May 2025 Registered for Cervical cancer (Combination therapy, Metastatic disease, Second-line therapy or greater, Recurrent) in China (IV)
- 01 Apr 2025 Efficacy data from a phase III trial in Squamous cell carcinoma released by Jiangsu HengRui Medicine